The short answer
Medicinal amounts of fenugreek can lower glucose, so use with glimepiride calls for a clinician-guided monitoring plan. Serious reports involve insulin, while the available glimepiride co-use study tested a mixture. The exact added risk and a protective spacing interval remain unestablished.
What this answer covers
Trigonella foenum-graecum seed preparations with oral glimepiride; medicinal amounts, culinary use and mixed products must be distinguished.
- Supplement or preparation
- Fenugreek
- Medication ingredient
- glimepiride
The glimepiride co-use evidence involves a mixture
A study used chapatis containing both fenugreek and Nigella sativa alongside varied background treatment, including glimepiride in some participants. Improvements cannot be assigned to fenugreek alone. It did not quantify hypoglycemia in the glimepiride subgroup.
Serious low-glucose reports used a different medicine
A case series described hypoglycemic coma during use of authenticated fenugreek seeds with premixed insulin. The author considered the association possible to probable. These reports support caution, but are not a measured glimepiride interaction or a frequency estimate.
Amount and preparation deserve review
General safety guidance warns that large amounts can cause harmful low blood sugar. Ordinary seasoning and a medicinal seed preparation are different exposures. Discuss the actual product, other ingredients and your full diabetes regimen with the prescriber.
Do not rely on a spacing shortcut
No established number of hours removes possible overlapping glucose lowering. Follow the agreed monitoring plan when the supplement or medicine changes and seek help for low readings or symptoms according to your diabetes care instructions. Do not independently lower or stop prescribed treatment.
Evidence and practical considerations
Side effects & toxicity
Medicinal amounts of fenugreek can lower glucose, so use with glimepiride calls for a clinician-guided monitoring plan. Serious reports involve insulin, while the available glimepiride co-use study tested a mixture. The exact added risk and a protective spacing interval remain unestablished.
- Exact scope
- Trigonella foenum-graecum seed preparations with oral glimepiride; medicinal amounts, culinary use and mixed products must be distinguished. with Oral glimepiride tablets for type 2 diabetes.
- Medication form and route
- oral
What remains uncertain
- No quantified exact-pair risk or protective spacing interval is established. Original-source access and population limitations are documented individually.
Factors that may matter: Exact preparation and amount; Other glucose-lowering treatment; Meal schedule, kidney function and glucose readings.
Read the supporting source summaries
Source 1: Current U.S. regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with type 2 diabetes using oral glimepiride.
Glimepiride can cause severe hypoglycemia. Nicotinic acid is listed among agents that may reduce glucose control. The specified four-hour-before instruction applies to colesevelam.
How this applies: Exact medication labeling provides administration and monitoring context, not proof of untested supplement effects.
The label does not establish every botanical interaction. Colesevelam instructions cannot be transferred to charcoal, glucomannan or other supplements.
Source 2: Original human clinical study
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Overweight and diabetic adults, including some taking glimepiride.
Several metabolic measures improved; the paper did not report adverse renal or hepatic effects.
How this applies: Actual co-use is documented but cannot isolate fenugreek effects or establish a severe-hypoglycemia rate.
Uncontrolled multicomponent intervention, mixed medicines and no quantified glimepiride-subgroup hypoglycemia outcome. The paper contains unrelated enzyme assertions not adopted here.
Source 3: Original clinical case series
link.springer.com · Source check Sep 10, 2026
Population: Four people using premixed insulin and authenticated fenugreek seeds.
Hypoglycemic coma was reported; the author assessed causality as possible to probable.
How this applies: Supports a glucose-monitoring precaution, while explicitly retaining the medication difference.
Observational reports with insulin, not glimepiride. Cannot determine an incidence, prove causality or establish a safe seed dose.
Source 4: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People taking fenugreek in supplement amounts.
Large doses may cause a harmful drop in blood sugar.
How this applies: Supports individualized glucose monitoring when medicinal amounts are added.
General guidance, not a glimepiride interaction trial or a quantified dose-response threshold.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial source-checked research draft. Exact preparations, contrary findings and study limitations documented; clinical review not recorded. | |
| Research summary published |
Article revision: 9e3969e274b6d626
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.